Dr Chari on the MonumenTAL-1 Trial Examining Talquetamab in Multiple Myeloma

Ajay Chari, MD, professor of medicine, director of Clinical Research, Multiple Myeloma Program, Icahn School of Medicine at Mount Sinai, discusses findings from the phase 1/2 MonumenTAL-1 trial (NCT04634552) investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

Data on 2 different recommended phase 2 doses of talquetamab were presented at the 2022 ASH Annual Meeting.

When administered at a 0.4 mg/kg weekly dose, talquetamab elicited an overall response rate (ORR) of 74.1%, according to Chari. The 0.8 mg/kg weekly dose of the agent produced an ORR of 73.1%. Notably, 31.1% of patients in the 0.4-mg/kg cohort and 28.9% of those in the 0.8-mg/kg cohort had high-risk cytogenetics, Chari explains.

Historically, an ORR of 20% or better could be enough to support the approval of an agent for the treatment of patients with this disease, Chari says. Talquetamab represents another promising agent in the era of T-cell redirection that could deliver durable remissions to patients who previously had no options, Chari concludes.